PDEPT: Polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-β-lactamase and HPMA copolymer-C-Dox as a model combination

Bioconjugate Chemistry

Volumn 14, Issue 4, 2003, Pages 797-804

  Satchi Fainaro, Ronit ^a,b   Hailu, Hanna ^c   Davies, John W ^d   Summerford, Clive ^d   Duncan, Ruth ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d Polymer Laboratories Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; ENZYMES; TARGETED DRUG DELIVERY; TUMORS;

ANTI-TUMORS; CATHEPSIN B; CYTOTOXIC DRUGS; DOXORUBICIN; ENZYME-PRODRUG THERAPIES; METHACRYLAMIDES; MODEL COMBINATION; POLYMERIC PRODRUGS; TUMOR SITE; Β-LACTAMASE;

MOLECULAR WEIGHT;

COPOLYMER; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER METHACRYLOYLGLYCYLGLYCINE BETA LACTAMASE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER METHACRYLOYLGLYCYLGLYCINE CEPHALOSPORIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRAFT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MELANOMA; MOUSE; NONHUMAN; POLYMER DIRECTED ENZYME PRODRUG THERAPY;

ANIMALIA;

EID: 0038793489     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc020091k     Document Type: Article

References (32)

1. Veronese, F. M. (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22, 405-417.
2. Duncan, R. (2003) Polymer-Anticancer Drug Conjugates. Biomedical Aspects of Drug Targeting (V. Muzyknantov and V. Torchilin, Eds.) pp 193-210, Kluwer Acadmic Publishers, Boston, in press.
3. Francis, G. E., Delgado, C., and Fisher, D. (1992) PEG-modified proteins. Stability of proteins pharmaceuticals (Part B) (M. M. Ahem, Ed.) pp 235-263, Plenum Press, New York.
4. Francis, G. E., Fisher, D., Delgado, C., Malik, F., Gardiner, A., and Neale, D. (1998) PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int. J. Hematol. 68, 1-18.
5. Gianasi, E., Wasil, M., Evagorou, E. G., Keddle, A., Wilson, G., and Duncan, R. (1999) HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumor activity in vivo. Eur. J. Cancer 35, 994-1002.
6. Seymour, L. W., Ulbrich, K., Strohalm, J., Kopecek, J., and Duncan, R. (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39, 1125-1131.
7. Li, C., Ke, S., Wu, Q. P., Tansey, W., Hunter, N., Buchmiller, L. M., Milas, L., Charnsangavej, C., and Wallace, S. (2000) Tumor irradiation enhances the tumor-specific distribution of poly(L- glutamic acid)-conjugated paclitaxel and its anti-tumor efficacy. Clin. Cancer Res. 6, 2829-2834.
8. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 65, 271-284.
9. Satchi, R., Connors, T. A., and Duncan, R. (2001) PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85, 1070-1076.
10. Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., and Cassidy, J. (1999) Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5, 83-94.
11. Mascaretti, O. A., Danelon, G. O., Laborde, M., Mata, E. G., and Setti, E. L. (1999) Recent advances in the chemistry of beta-lactam compounds as selected active-site serine beta-lactamase inhibitors. Curr. Pharm. Des. 5, 939-953.
12. Svensson, H. P., Kadow, J. F., Vrudhula, V. M., Wallace, P. M., and Senter, P. D. (1992) Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjugate Chem. 3, 176-181.
13. Rodrigues, M. L., Carter, P., Wirth, C., Mullins, S., Lee, A., and Blackburn, B. K. (1995) Synthesis and beta-lactamase-mediated activation of a cephalosporin- taxol prodrug. Chem. Biol. 2, 223-227.
14. Senter, P. D., Svensson, H. P., Schreiber, G. J., Rodriguez, J. L., and Vrudhula, V. M. (1995) Poly(ethylene glycol)-doxorubicin conjugates containing beta-lactamase-sensitive linkers. Bioconjugate Chem. 6, 389-394.
15. Vrudhula, V. M., Svensson, H. P., and Senter, P. D. (1995) Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-beta-lactamase conjugates. J. Med. Chem. 38, 1380-1385.
16. Knox, R. J., Melton, R. G., and Satchi, R. (2002) Enzyme-prodrug therapies of cancer. Polymeric Biomaterials (S. Dumitriu, Ed.) 2nd ed., pp 895-927, Marcel Dekker, New York.
17. Rihova, B., Bilej, M., Vetvicka, V., Ulbrich, K., Strohalm, J., Kopecek, J., and Duncan, R. (1989) Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10, 335-342.
18. Chapman, A. P. (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54, 531-545.
19. Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D., and Boyd, M. R. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827-4833.
20. Bolton, A. E. and Hunter, W. M. (1973) The labeling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem. J. 133, 529-539.
21. Duncan, R. (2002) Polymer-Drug Conjugates. Handbook of Anticancer Drug Development (Budman, Calvert, and Rowinsky, Eds.) Lippincott Williams & Wilkins (in press).
22. Svensson, H. P., Wallace, P. M., and Senter, P. D. (1994) Synthesis and characterization of monoclonal antibody-beta-lactamase conjugates. Bioconjugate Chem. 5, 262-267.
23. Niculescu-Duvaz, I., Friedlos, F., Niculescu-Duvaz, D., Davies, L., and Springer, C. J. (1999) Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des. 14, 517-538.
24. Seymour, L. W., Ulbrich, K., Styger, P. S., Brereton, M., Subr, V., Strohalm, J, Duncan, R. (1994) Tumoritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70, 636-641.
25. Delgado, C., Francis, G. E., and Fisher, D. (1992) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249-304.
26. Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S., Hume, I. C., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., Grandi, M., Ripamonti, M., Farao, M., Suarato, A. (1992) Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release 19, 331-346.
27. Springer, C. J., Bagshawe, K. D., Sharma, S. K., Searle, F., Boden, J. A., Antoniw, P., Burke, P. J., Rogers, G. T., Sherwood, R. F., and Melton, R. G. (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody- directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 27, 1361-1366.
28. Martin, J., Stribbling, S. M., Poon, G. K., Begent, R. H., Napier, M., Sharma, S. K., and Springer, C. J. (1997) Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother. Pharmacol. 40, 189-201.
29. Bagshawe, K. D., and Sharma, S. K. (1996) Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc. 28, 3156-3158.
30. Rihova, B., Kopecek, J., Ulbrich, K., Pospisil, M., and Mancal, P. (1984) Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 5, 143-148.
31. Abuchowski, A., Davis, F. F., and Davis, S. (1981) Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to poly-(ethylene glycol) in man. Cancer Treat Rep. 65, 1077-1081.
32. Satchi, R. (1999) PDEPT: Polymer directed enzyme prodrug therapy. Ph.D. Thesis, pp 193-207, London: University of London.